AzurRx BioPharma, Inc. (AZRX)

AzurRx BioPharma, Inc. (AZRX) — VMCI valuation read

Across 120 indicators, AzurRx BioPharma, Inc. (AZRX) lands at VMCI 48/100. The Healthcare sector median is 50, so the 2-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on AZRX in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, AZRX trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of -0.6x leaves covenant headroom for AZRX on the trailing balance sheet.

AZRX fell 1.4% over the trailing 7 days, with a -17.2% read on a 30-day basis.